Al Bakr AI, AlOmar RS, Nada MAF, et al. - Researchers determined the time to start anticoagulation therapy in acute ischemic stroke (AIS) with non-valvular AF with respect to safety and efficacy by identifying the rate of intracranial hemorrhage (ICH) and recurrent ischemic symptoms during follow-up. In this prospective observational cohort study, they assessed 120 patients with AIS/TIAs from July 2016 to July 2018. Patients who received anticoagulants 1–6 days comprised Group I (45.83%), 7–14 days comprised Group II (35%), and > 14 days after the ischemic event comprised Group III (19.17%). ICH occurred in 26.67% (n = 32) of patients. Upon analysis, the investigators noted a correlation between early initiation of anticoagulation after stroke, especially in cases of large infarction, and a significant risk of ICH. With warfarin, this risk was highest, and with DOAC, the lowest. However, no differences were observed in functional outcome among patients with and without ICH. A possible relation of ethnicity of the local population with a higher incidence of ICH was identified, given the FDA recommendation of the use of lower doses of VKA in the Asian population.